Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

November 30, 2017November 30, 2017

Early Use of Effective Lupus Therapies May Reduce Healthcare Costs, Canadian Study Finds

News

Patients with more severe damage caused by systemic lupus erythematosus spend four times as much on healthcare than those with the lowest levels of lupus damage, Canadian researchers said ... Read more

October 6, 2017

Yogurt Bacteria Improved Lupus Kidney Disease in Mice, Study Shows

News

Good gut bacteria from yogurt may be able to reduce kidney inflammation in systemic lupus erythematosus patients — if results of a mouse study can be translated to humans, that ... Read more

September 26, 2017

Gut Bacteria May Help Prevent Heart Disease in Lupus, Mice Study Finds

News

Good gut bacteria might prevent disease processes leading to heart disease in patients with systemic lupus erythematosus, according to a mice study that appeared in the journal PLOS ONE. ... Read more

September 20, 2017

Patient-reported Outcome Tool Fares Well, But Has Limitations, Study Finds

News

A tool for measuring patient-reported outcomes, called PROMIS-29, performed rather well in a study attempting to validate the approach in patients with systemic lupus erythematosus and other rheumatic conditions. ... Read more

September 5, 2017

TxCell Will Discuss Using Computer Simulations to Optimize Its Lupus Nephritis Immunotherapy

News

TxCell will do two presentations in Boston on its use of computer simulations to pack the most punch into the gene therapy it has developed against the kidney disease lupus nephritis ... Read more

August 18, 2017August 18, 2017

Lupus Patients Have Increased Risk of Cardiovascular and Metabolic Disease, Study Shows

News

Patients with systemic lupus erythematosus have an increased risk for cardiovascular and metabolic diseases — a risk that they share with patients who have other chronic inflammatory conditions, according ... Read more

July 13, 2017July 13, 2017

Phase 2 Trial of Neovacs’ Lupus Interferon Immunotherapy Receives Another Review Board Sign-off

News

Neovacs’ Phase 2b clinical trial of an interferon immunotherapy for lupus is going according to plan, the company announced after an independent review board declined to recommend modifications to the ... Read more

June 27, 2017June 27, 2017

Participants Being Sought for Online Survey of Lupus Patients’ Blood Types

News

An ongoing online survey to examine the distribution of blood types among lupus patients could provide important information about why people develop the disease, researchers say. The survey is a collaboration ... Read more

June 22, 2017June 22, 2017

Cause of Neuropsychiatric Ills Common to Lupus Seen in Study, Potential Treatment Raised

News

Neuropsychiatric symptoms in people with systemic lupus erythematosus may be caused by increased levels of the inflammatory molecule interferon-alpha in their brains, according to a study published in the journal Nature. ... Read more

June 20, 2017June 20, 2017

Celgene’s CC-220 Seen to Benefit Lupus Patients, But Researchers Urge Caution

News

A Phase 2a trial (NCT02185040) evaluating Celgene International‘s CC-220 in systemic lupus erythematosus (SLE) reports promising results, according to data presented at the Annual European Congress of Rheumatology (EULAR) 2017, held June ... Read more

Pin It on Pinterest